Rhenman & Partners Asset Management’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $39.2M | Buy |
625,000
+193,793
| +45% | +$15.5M | 4.84% | 1 |
|
|
2025
Q4 | $41.1M | Sell |
431,207
-6,793
| -2% | -$666K | 3.84% | 3 |
|
|
2025
Q3 | $42.8M | Buy |
438,000
+142,000
| +48% | +$14.7M | 4.73% | 1 |
|
|
2025
Q2 | $31.8M | Sell |
296,000
-4,000
| -1% | -$405K | 4.02% | 2 |
|
|
2025
Q1 | $30.3M | Sell |
300,000
-144,000
| -32% | -$14.5M | 3.48% | 5 |
|
|
2024
Q4 | $39.7M | Sell |
444,000
-146,000
| -25% | -$12.9M | 4.08% | 1 |
|
|
2024
Q3 | $49.4M | Sell |
590,000
-5,000
| -0.8% | -$394K | 4.01% | 1 |
|
|
2024
Q2 | $45.8M | Buy |
595,000
+13,000
| +2% | +$952K | 4.4% | 3 |
|
|
2024
Q1 | $39.9M | Sell |
582,000
-168,000
| -22% | -$10.8M | 3.78% | 4 |
|
|
2023
Q4 | $43.4M | Buy |
750,000
+50,000
| +7% | +$2.67M | 4.33% | 3 |
|
|
2023
Q3 | $37M | Buy |
700,000
+120,000
| +21% | +$6.29M | 3.98% | 2 |
|
|
2023
Q2 | $31.4M | Sell |
580,000
-20,000
| -3% | -$1.04M | 3.31% | 4 |
|
|
2023
Q1 | $29.8M | Buy |
600,000
+15,000
| +3% | +$707K | 3.27% | 3 |
|
|
2022
Q4 | $27.1M | Sell |
585,000
-110,000
| -16% | -$4.76M | 2.82% | 4 |
|
|
2022
Q3 | $30M | Sell |
695,000
-30,000
| -4% | -$1.2M | 3.14% | 3 |
|
|
2022
Q2 | $27M | Buy |
725,000
+215,000
| +42% | +$8.75M | 3.07% | 7 |
|
|
2022
Q1 | $22.6M | Sell |
510,000
-400,000
| -44% | -$17.3M | 2.23% | 12 |
|
|
2021
Q4 | $39.1M | Buy |
910,000
+340,000
| +60% | +$14.3M | 2.6% | 10 |
|
|
2021
Q3 | $24.7M | Buy |
570,000
+50,000
| +10% | +$2.21M | 1.74% | 18 |
|
|
2021
Q2 | $22.2M | Sell |
520,000
-150,000
| -22% | -$6.31M | 1.51% | 25 |
|
|
2021
Q1 | $25.9M | Buy |
670,000
+140,000
| +26% | +$5.3M | 1.81% | 18 |
|
|
2020
Q4 | $19.1M | Buy |
530,000
+80,000
| +18% | +$2.88M | 1.55% | 27 |
|
|
2020
Q3 | $17.2M | Buy |
450,000
+40,000
| +10% | +$1.54M | 1.53% | 27 |
|
|
2020
Q2 | $14.4M | Sell |
410,000
-155,000
| -27% | -$5.58M | 1.56% | 28 |
|
|
2020
Q1 | $18.4M | Buy |
565,000
+113,332
| +25% | +$4.43M | 2.58% | 10 |
|
|
2019
Q4 | $20.4M | Buy |
451,668
+81,668
| +22% | +$3.42M | 2.24% | 8 |
|
|
2019
Q3 | $15.1M | Sell |
370,000
-17,908
| -5% | -$759K | 1.89% | 19 |
|
|
2019
Q2 | $16.7M | Buy |
387,908
+20,000
| +5% | +$769K | 1.84% | 21 |
|
|
2019
Q1 | $14.1M | Sell |
367,908
-10,000
| -3% | -$382K | 1.65% | 23 |
|
|
2018
Q4 | $13.4M | Buy |
377,908
+39,940
| +12% | +$1.45M | 1.53% | 32 |
|
|
2018
Q3 | $13M | Sell |
337,968
-10,000
| -3% | -$349K | 1.3% | 36 |
|
|
2018
Q2 | $11.4M | Hold |
347,968
| – | – | 1.16% | 41 |
|
|
2018
Q1 | $9.51M | Hold |
347,968
| – | – | 1.17% | 36 |
|
|
2017
Q4 | $8.63M | Buy |
347,968
+67,500
| +24% | +$1.86M | 1.17% | 32 |
|
|
2017
Q3 | $8.18M | Buy |
+280,468
| New | +$7.75M | 1.04% | 36 |
|
|
2016
Q1 | – | Sell |
-274,000
| Closed | -$5.05M | – | 93 |
|
|
2015
Q4 | $5.05M | Buy |
+274,000
| New | +$4.91M | 0.76% | 49 |
|
|
2014
Q4 | – | Sell |
-214,000
| Closed | -$2.53M | – | 86 |
|
|
2014
Q3 | $2.53M | Sell |
214,000
-201,000
| -48% | -$2.53M | 0.74% | 49 |
|
|
2014
Q2 | $5.3M | Buy |
415,000
+130,022
| +46% | +$1.69M | 1.57% | 15 |
|
|
2014
Q1 | $3.85M | Buy |
284,978
+9,978
| +4% | +$131K | 1.16% | 29 |
|
|
2013
Q4 | $3.31M | Buy |
+275,000
| New | +$3.25M | 1.29% | 23 |
|
Other funds holding BSX
VCM
VPM
Rhenman & Partners Asset Management's BSX Position: Q1 2026 in Review
Rhenman & Partners Asset Management increased its Boston Scientific (BSX) stake by 45% in Q1 2026, buying an estimated $15.5M and bringing the position to 625,000 shares worth $39.2M. The position accounts for 4.84% of the portfolio, ranked #1.
Rhenman & Partners Asset Management first reported a position in BSX in Q4 2013 and has held it in 40 quarters since. The position peaked at $49.4M in Q3 2024. 1,666 funds tracked by Wall St. Rank hold BSX as of Q1 2026.
- Rhenman & Partners Asset Management held 625,000 shares of Boston Scientific worth $39.2M as of Q1 2026.
- Rhenman & Partners Asset Management bought 193,793 Boston Scientific shares in Q1 2026, an estimated $15.5M.
- Boston Scientific made up 4.84% of Rhenman & Partners Asset Management's portfolio in Q1 2026, its #1 holding.
- Rhenman & Partners Asset Management first reported a position in Boston Scientific in Q4 2013 and has held it in 40 quarters since.
- Rhenman & Partners Asset Management's Boston Scientific position peaked at $49.4M in Q3 2024.
- 1,666 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.
Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.